Skip to main content

Table 2 Incidence of proliferative and apoptotic CTCs in CTC-positive DC and metastatic patients and their percentages among the total CTCs detected

From: Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy

  CTC phenotype (n%)
Patient groups I II III IV
  Dormant only a Proliferative b Apoptotic c All phenotypes e
Dormancy candidates (n = 40) 25 (62.5) 7 (17.5) 4 (10) 4 (10)
Metastatic patients (n = 15) 8 (53.4) 7 (46.6)* 0 (0) 0 (0)
  CTC phenotype (n %)
  Dormant a      Nondormant d
Number of CTCs   Proliferative b Apoptotic c
Dormancy candidates (n = 244) 201 (82.4) 14 (5.7) 29 (11.9)
Metastatic patients (n = 142) 84 (59.1)** 58 (40.9)** 0 (0)
  1. Patients with aKi67(-)/M30(-) CTCs, bKi67(+)/M30(-) CTCs, cKi67(-)/M30(+) CTCs, dKi67(+)/M30(-) or Ki67(-)/M30(+) CTCs and epatients harboring all phenotypes. *P = 0.0394, **P <0.0001, compared to dormancy candidates. CTCs, circulating tumor cells; DC, dormancy candidates.